# Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation

> **NCT04687111** · PHASE2 · UNKNOWN · sponsor: **Mark Ledwidge** · enrollment: 250 (actual)

## Conditions studied

- Atrial Remodeling
- Myocardial Dysfunction
- Left Ventricular Remodeling
- Left Ventricular Diastolic Dysfunction
- Hypertension
- Cardiovascular Morbidity
- Fibrosis Myocardial
- Inflammatory Myopathy
- Atrial Arrhythmia

## Interventions

- **DRUG:** Sacubitril-Valsartan
- **DRUG:** Valsartan

## Key facts

- **NCT ID:** NCT04687111
- **Lead sponsor:** Mark Ledwidge
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-12-16
- **Primary completion:** 2021-06-11
- **Final completion:** 2021-06-11
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2021-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04687111

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04687111, "Personalised Prospective Comparison of ARni With ArB in Patients With Natriuretic Peptide eLEvation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT04687111. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*